


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-104) EDASALONEXENT
PRONUNCIATION e da sa" lo nex' ent
THERAPEUTIC CLAIM Treatment of Duchenne muscular dystrophy (DMD)
CHEMICAL NAMES

1. Benzamide, 2-hydroxy-*N*-[2-[[[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl]amino]ethyl]- (CAS Name)
2. *N*-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]ethyl}-2-hydroxybenzamide (IUPAC Name)

STRUCTURAL FORMULA



MOLECULAR FORMULA C₃₁H₄₂N₂O₃
MOLECULAR WEIGHT 490.7
TRADEMARKS None as of yet
SPONSOR Catabasis Pharmaceuticals, Inc.
CODE DESIGNATIONS CAT-1004
CAS REGISTRY NUMBER 1204317-86-1
UNII AF3Z6434KS
WHO NUMBER 10223

SCS